Table 1. Patients’ baseline characteristics.
| Patients (n = 38) | |
|---|---|
| Age | |
| Median (range)–years | 68 (41–81) |
| Sex–no. (%) | |
| Male | 17 (44.74) |
| Female | 21 (55.26) |
| Smoking status–no. (%) | |
| Never | 0 (0) |
| Current | 24 (63.16) |
| Former | 14 (36.84) |
| ECOG performance status–no. (%) | |
| 0 | 11 (28.95) |
| 1 | 19 (50.00) |
| 2 | 8 (21.05) |
| Metastasis sites–no. (%) | |
| Liver | 18 (47.37) |
| Bone | 18 (47.37) |
| Adrenal gland | 15 (39.47) |
| Brain | 7 (18.42) |
| Treatments | |
| I line–no. (%) | 38 (100) |
| Carboplatin plus etoposide | 34 (89.47) |
| Cisplatin plus etoposide | 4 (10.53) |
| Number of cycles | |
| ≤3 | 12 (31.58) |
| 4–6 | 26 (68.42) |
| II line–no. (%) | 8 (21.05) |
| III line–no. (%) | 3 (7.89) |
| Best response to treatment–no. (%) | |
| Complete response | 1 (2.63) |
| Partial response | 21 (56.26) |
| Stable disease | 1 (2.63) |
| Progression disease | 15 (39.47) |
| Radiotherapy–no. (%) | |
| Chest/mediastin | 7 (18.42) |
| Bone | 4 (10.53) |
| Brain | 4 (10.53) |
| Liver | 0 (0) |
| Adrenal gland | 0 (0) |
| PCI–no. (%) | 5 (13.16) |